Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi's Dupixent Wins Approval in Pediatric EoE | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Sanofi’s Dupixent Wins Approval in Pediatric EoE

Becomes the first and only medicine approved in the U.S. specifically indicated to treat pediatric patients aged 1 to 11 years.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The U.S. FDA has approved Sanofi’s Dupixent (dupilumab) for the treatment of pediatric patients aged 1 to 11 years with eosinophilic esophagitis (EoE). Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients. 

This approval expands the initial FDA approval for EoE in May 2022 for patients aged 12 years and older. The FDA evaluated Dupixent for this expanded indication under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in treating serious conditions.
 
EoE is a chronic, progressive disease driven in part by type 2 inflammation that damages the esophagus and impairs its function. EoE can severely impact a child’s ability to eat, and they may experience heartburn, vomiting, abdominal discomfort, trouble swallowing, food refusal and failure to thrive. Approximately 21,000 children under the age of 12 in the U.S. are currently being treated for EoE with unapproved therapies. 
 
Naimish Patel, M.D., Head of Global Development, Immunology and Inflammation at Sanofi, said, “Young children with eosinophilic esophagitis have significant unmet medical needs; despite existing treatment options, 40% of these children in the U.S. under the age of 12 continue to experience symptoms of this disease. Today’s approval underscores our commitment to bringing therapies to young patients with unmet needs and also brings hope to these patients who are at a critical age where struggling to eat and maintain weight directly impacts their overall nutritional intake and development.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics